Idarubicin in the therapy of acute myeloid leukemia: Final analysis in 57 previously untreated patients

G. L. Deliliers, C. Annaloro, A. Oriani, E. Pozzoli, A. Cortelezzi, M. Cortellaro, R. Mozzana, A. D. Volpe, D. Soligo, E. Cofrancesco, C. Boschetti, E. E. Polli

Research output: Contribution to journalArticle

Abstract

Fifty-seven previously untreated adult acute myeloid leukemia patients received idarubicin (IDA) in sequential combination with cytarabine as induction therapy; post-remission treatment included two courses of IDA and cytarabine alternating with two courses of VP-16 and cytarabine. As late intensification, patients received either high-dose cytarabine or, in 10 cases, autologous bone marrow transplantation. Complete remission (CR) was achieved in 48 patients (84.2%), 41 after one induction course and seven after two courses. Median length of disease-free survival (DFS) was 26 months. Univariate analysis did not identify any of the investigated variables as having prognostic significance in predicting DFS. On the other hand, patients achieving CR after one induction course had a better DFS than those requiring two courses. Furthermore, the analysis of DFS slightly favors autologous bone marrow transplantation. In conclusion, the antileukemic activity of the present IDA protocol is testified by the high CR rate and by the possibility of minimizing the role of prognostic factors. The better outcome of patients achieving CR after one induction course further supports the opinion that the intensity of the induction treatment, offered by an agent as potent as IDA, might significantly influence DFS.

Original languageEnglish
Pages (from-to)27-33
Number of pages7
JournalSeminars in Oncology
Volume20
Issue numberSUPPL. 8
Publication statusPublished - 1993

Fingerprint

Idarubicin
Acute Myeloid Leukemia
Disease-Free Survival
Cytarabine
Autologous Transplantation
Bone Marrow Transplantation
Therapeutics
Etoposide

ASJC Scopus subject areas

  • Oncology

Cite this

Deliliers, G. L., Annaloro, C., Oriani, A., Pozzoli, E., Cortelezzi, A., Cortellaro, M., ... Polli, E. E. (1993). Idarubicin in the therapy of acute myeloid leukemia: Final analysis in 57 previously untreated patients. Seminars in Oncology, 20(SUPPL. 8), 27-33.

Idarubicin in the therapy of acute myeloid leukemia : Final analysis in 57 previously untreated patients. / Deliliers, G. L.; Annaloro, C.; Oriani, A.; Pozzoli, E.; Cortelezzi, A.; Cortellaro, M.; Mozzana, R.; Volpe, A. D.; Soligo, D.; Cofrancesco, E.; Boschetti, C.; Polli, E. E.

In: Seminars in Oncology, Vol. 20, No. SUPPL. 8, 1993, p. 27-33.

Research output: Contribution to journalArticle

Deliliers, GL, Annaloro, C, Oriani, A, Pozzoli, E, Cortelezzi, A, Cortellaro, M, Mozzana, R, Volpe, AD, Soligo, D, Cofrancesco, E, Boschetti, C & Polli, EE 1993, 'Idarubicin in the therapy of acute myeloid leukemia: Final analysis in 57 previously untreated patients', Seminars in Oncology, vol. 20, no. SUPPL. 8, pp. 27-33.
Deliliers GL, Annaloro C, Oriani A, Pozzoli E, Cortelezzi A, Cortellaro M et al. Idarubicin in the therapy of acute myeloid leukemia: Final analysis in 57 previously untreated patients. Seminars in Oncology. 1993;20(SUPPL. 8):27-33.
Deliliers, G. L. ; Annaloro, C. ; Oriani, A. ; Pozzoli, E. ; Cortelezzi, A. ; Cortellaro, M. ; Mozzana, R. ; Volpe, A. D. ; Soligo, D. ; Cofrancesco, E. ; Boschetti, C. ; Polli, E. E. / Idarubicin in the therapy of acute myeloid leukemia : Final analysis in 57 previously untreated patients. In: Seminars in Oncology. 1993 ; Vol. 20, No. SUPPL. 8. pp. 27-33.
@article{3aec77b26d2748aaa05faff6cec84b97,
title = "Idarubicin in the therapy of acute myeloid leukemia: Final analysis in 57 previously untreated patients",
abstract = "Fifty-seven previously untreated adult acute myeloid leukemia patients received idarubicin (IDA) in sequential combination with cytarabine as induction therapy; post-remission treatment included two courses of IDA and cytarabine alternating with two courses of VP-16 and cytarabine. As late intensification, patients received either high-dose cytarabine or, in 10 cases, autologous bone marrow transplantation. Complete remission (CR) was achieved in 48 patients (84.2{\%}), 41 after one induction course and seven after two courses. Median length of disease-free survival (DFS) was 26 months. Univariate analysis did not identify any of the investigated variables as having prognostic significance in predicting DFS. On the other hand, patients achieving CR after one induction course had a better DFS than those requiring two courses. Furthermore, the analysis of DFS slightly favors autologous bone marrow transplantation. In conclusion, the antileukemic activity of the present IDA protocol is testified by the high CR rate and by the possibility of minimizing the role of prognostic factors. The better outcome of patients achieving CR after one induction course further supports the opinion that the intensity of the induction treatment, offered by an agent as potent as IDA, might significantly influence DFS.",
author = "Deliliers, {G. L.} and C. Annaloro and A. Oriani and E. Pozzoli and A. Cortelezzi and M. Cortellaro and R. Mozzana and Volpe, {A. D.} and D. Soligo and E. Cofrancesco and C. Boschetti and Polli, {E. E.}",
year = "1993",
language = "English",
volume = "20",
pages = "27--33",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "SUPPL. 8",

}

TY - JOUR

T1 - Idarubicin in the therapy of acute myeloid leukemia

T2 - Final analysis in 57 previously untreated patients

AU - Deliliers, G. L.

AU - Annaloro, C.

AU - Oriani, A.

AU - Pozzoli, E.

AU - Cortelezzi, A.

AU - Cortellaro, M.

AU - Mozzana, R.

AU - Volpe, A. D.

AU - Soligo, D.

AU - Cofrancesco, E.

AU - Boschetti, C.

AU - Polli, E. E.

PY - 1993

Y1 - 1993

N2 - Fifty-seven previously untreated adult acute myeloid leukemia patients received idarubicin (IDA) in sequential combination with cytarabine as induction therapy; post-remission treatment included two courses of IDA and cytarabine alternating with two courses of VP-16 and cytarabine. As late intensification, patients received either high-dose cytarabine or, in 10 cases, autologous bone marrow transplantation. Complete remission (CR) was achieved in 48 patients (84.2%), 41 after one induction course and seven after two courses. Median length of disease-free survival (DFS) was 26 months. Univariate analysis did not identify any of the investigated variables as having prognostic significance in predicting DFS. On the other hand, patients achieving CR after one induction course had a better DFS than those requiring two courses. Furthermore, the analysis of DFS slightly favors autologous bone marrow transplantation. In conclusion, the antileukemic activity of the present IDA protocol is testified by the high CR rate and by the possibility of minimizing the role of prognostic factors. The better outcome of patients achieving CR after one induction course further supports the opinion that the intensity of the induction treatment, offered by an agent as potent as IDA, might significantly influence DFS.

AB - Fifty-seven previously untreated adult acute myeloid leukemia patients received idarubicin (IDA) in sequential combination with cytarabine as induction therapy; post-remission treatment included two courses of IDA and cytarabine alternating with two courses of VP-16 and cytarabine. As late intensification, patients received either high-dose cytarabine or, in 10 cases, autologous bone marrow transplantation. Complete remission (CR) was achieved in 48 patients (84.2%), 41 after one induction course and seven after two courses. Median length of disease-free survival (DFS) was 26 months. Univariate analysis did not identify any of the investigated variables as having prognostic significance in predicting DFS. On the other hand, patients achieving CR after one induction course had a better DFS than those requiring two courses. Furthermore, the analysis of DFS slightly favors autologous bone marrow transplantation. In conclusion, the antileukemic activity of the present IDA protocol is testified by the high CR rate and by the possibility of minimizing the role of prognostic factors. The better outcome of patients achieving CR after one induction course further supports the opinion that the intensity of the induction treatment, offered by an agent as potent as IDA, might significantly influence DFS.

UR - http://www.scopus.com/inward/record.url?scp=0027769489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027769489&partnerID=8YFLogxK

M3 - Article

C2 - 8290969

AN - SCOPUS:0027769489

VL - 20

SP - 27

EP - 33

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - SUPPL. 8

ER -